BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Earnings Results, Meets Estimates

BioCryst Pharmaceuticals (NASDAQ:BCRX) released its earnings results on Monday. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07), Briefing.com reports. The company had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. BioCryst Pharmaceuticals’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.19) earnings per share.

BioCryst Pharmaceuticals Stock Down 1.4 %

BCRX stock traded down $0.10 during midday trading on Tuesday, reaching $7.25. 1,150,617 shares of the company’s stock traded hands, compared to its average volume of 2,965,821. The company has a 50-day simple moving average of $7.84 and a two-hundred day simple moving average of $6.95. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.88. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -11.87 and a beta of 1.89.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday. JMP Securities lifted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 6th. Barclays raised their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $14.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. Finally, StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $14.67.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.